Sunshine Biopharma Inc. (SBFMW) balance sheet

SBFMWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SBFM

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 10/30

$0.03+0.00 (+2.00%)

Close on Oct 30, 2026Market cap $11.36MP/E –Yield –

Sunshine Biopharma Inc. balance sheet

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Cash & Equivalents	9.12	9.69	16	22	2.05	0.99	0.04	0.12	0.11	0.06	0.05	0.14	0.03	0.13	0.06	0.16	0.11
Cash & Short-Term Investments	9.12	9.69	16	22	2.05	0.99	0.04	0.12	0.11	0.06	0.05	0.14	0.03	0.13	0.06	0.16	0.11
Receivables	3.46	3.87	2.55	1.91	0.01	0.00	0.00	0	0	–	0.00	0	–	–	–	–	–
Inventory	13	11	5.73	3.29	0.11	0.02	0.02	0	–	–	–	–	–	–	–	–	–
Prepaid Expenses & Other	0.80	1.13	0.31	0.28	0.03	0.00	0.00	0.00	0.01	0.00	0.00	0	0	0.00	0.05	0.05	–
Total Current Assets	27	26	25	27	2.20	1.03	0.07	1.10	0.12	0.06	0.05	0.14	0.03	0.13	0.11	0.21	–
Property, Plant & Equipment	0.56	0.55	0.37	0.39	0.01	0.02	0.03	0.05	0.06	0.01	0.00	0	–	–	–	–	–
Gross Property, Plant & Equipment	1.07	0.88	0.56	0.48	–	–	–	–	–	–	–	–	–	–	–	–	–
Accumulated Depreciation	-0.51	-0.34	-0.19	-0.08	-0.06	-0.05	-0.04	-0.02	-0.01	0.00	0.00	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	0.78	0.94	0.65	0.76	0	–	–	0	–	–	–	–	–	–	–	–	–
Goodwill	–	0	0	0	0	–	0.67	0.67	0	–	–	–	–	–	–	–	–
Intangible Assets	1.89	3.02	1.44	0.78	0	0	0	0	0	0	0.62	0	–	–	–	–	–
Total Assets	30	31	27	29	2.20	1.05	0.10	1.15	0.26	0.06	0.67	0.14	0.03	0.13	0.11	0.21	–
Accounts Payable	5.66	5.54	2.59	2.80	0.04	0.06	0.10	0.12	0.02	0.03	0.05	0.03	0.02	0.00	0.00	0.01	–
Accrued Expenses	–	–	–	–	–	–	–	–	–	–	0	–	–	–	–	–	–
Current Portion of Leases	0.22	0.21	0.12	0.12	0	–	–	0	–	–	–	–	–	–	–	–	–
Current Income Taxes Payable	0.27	0.27	0.30	0.37	0	–	–	–	–	–	–	–	–	–	–	–	–
Total Current Liabilities	6.44	6.31	5.55	6.93	0.09	1.05	0.83	0.91	0.75	0.27	1.27	0.53	–	–	–	–	–
Long-Term Debt	–	–	–	0	1.90	0.95	0	0.29	0.08	0	0.10	0	0	–	–	–	–
Long-Term Leases	0.60	0.74	0.54	0.64	0	–	–	0	–	–	–	–	–	–	–	–	–
Operating Lease Liabilities	0.81	0.95	0.66	0.77	0	–	–	0	–	–	–	–	–	–	–	–	–
Deferred Tax Liabilities	–	–	–	–	–	–	–	–	–	–	0	0	0	–	–	–	–
Other Long-Term Liabilities	–	–	–	–	–	–	–	–	–	0	0	0	–	–	–	–	–
Total Liabilities	7.04	7.06	6.14	7.62	1.99	2.00	0.83	1.20	0.83	0.27	1.27	0.53	0.04	0.06	0.00	0.01	–
Total Debt	–	–	–	0	1.90	0.95	0	0.29	0.08	0	0.10	0	0	–	–	–	–
Preferred Stock	0.01	0.01	0.00	0.00	0.10	0.10	–	–	0	0	0	0	0	0	0	0.07	–
Common Stock	0.00	0.00	0.00	0.02	0.00	0.00	0.04	0.00	0.05	0.77	0.20	0.07	0.06	0.05	0.05	0.03	–
Additional Paid-In Capital	98	93	84	81	33	19	17	16	13	12	8.24	6.97	5.43	3.02	2.35	1.83	–
Retained Earnings	-75	-69	-64	-59	-33	-20	-17	-16	-14	-13	-9.08	-7.43	-5.49	-3.00	-2.29	-1.74	–
Comprehensive Income & Other	-0.07	-0.83	0.70	0.16	-0.02	0.00	0.00	0.00	0.00	0.00	0.00	0	0	0	0	–	–
Shareholders' Equity	23	24	21	22	0.21	-0.95	-0.74	-0.06	-0.57	-0.21	-0.60	-0.39	-0.01	0.07	0.10	0.20	0.10
Total Equity	23	24	21	22	0.21	-0.95	-0.74	-0.06	-0.57	-0.21	-0.60	-0.39	-0.01	0.07	0.10	0.20	0.10
Total Liabilities & Equity	30	31	27	29	2.20	1.05	0.10	1.15	0.26	0.06	0.67	0.14	0.03	0.13	0.11	0.21	–
Shares Outstanding(shares)	0.49	2.58	0.01	0.23	0.03	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 30.3%
Operating margin: -16.6%
Net margin: -16.5%
Return on equity, FY2025: -25.7%

Financial strength

Current ratio: 5.46
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 244.7%

Valuation

P/E ratio: –
Price to sales: 0.32
Price to book: 0.41
Dividend yield: –